medigraphic.com
ISSN 2078-7170 (Electronic)

2011, Number 2

<< Back Next >>

CorSalud 2011; 3 (2)

Comparison of therapeutic strategies for the control of blood pressure and angina in patients with hypertension and chronic ischemic heart disease in the province of Villa Clara. Appendix of INVEST study

Nodarse VJR, Rodríguez LA, Moreno-Martínez FL, Ramírez GJI, Márquez EY, López BOJ

Language: Spanish
References: 55
Page: 78-89
PDF size: 435.11 Kb.


ABSTRACT

Background and Objectives: The treatment of hypertension and its complications are a worldwide problem. In our country nearly 25 % of the population over 15 years old is hypertensive, and this figure nearly doubles in those over 60. This research aims to compare two treatment strategies for controlling hypertension in outpatients with chronic coronary ischemic syndrome. Method: A total of 150 patients was included, 73 were randomized to receive calcium antagonist and non-calcium antagonist respectively, as 4 patients were subsequently excluded. Each was asked to sign consent, underwent clinical examination and a 12-lead, conventional electrocardiogram. Blood pressure and episodes of angina were evaluated at 6 months and one year. All variables were entered into a database and statistical analysis was performed using Student's t and Chi square. Results: The mean age was 61,5 years. Women and white skin color were predominant. At 12 months of treatment, blood pressure normalized in more than 80 % of patients without significant differences between the two treatment strategies. Over 75 % of patients in both groups controlled the angina episodes and more than 85 % said the quality of life was good. Conclusions: Control of blood pressure and angina was achieved and there were no significant differences between the two treatment strategies.


REFERENCES

  1. Ramírez M, Moreno-Martínez FL, Torres D, Nieto CG, Osorio CM, Guevara A, et al. Detección de hipertrofia ventricular izquierda en adolescentes con hipertensión arterial esencial. Hipertensión [Internet]. 2006 [citado 3 Mar 2011];23(9):[aprox. 5 p.]. Disponible en: http://www.elsevier.es/es/revistas/hipertension--riesgo-vascular-67/deteccion-hipertrofia-ventricular-izquierda-adolescentes-hipertension-arterial-13096119-originales-2006

  2. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud. La Habana: MINSAP; 2001.

  3. Moreno FL, López OJ, Llanes RJ, Cerero S, Rodrí-guez N. Obesidad: aspectos patogénicos, altera-ciones cardiovasculares asociadas y estrategias terapéuticas. Mapfre Medicina. 2005;16(3): 209-22.

  4. Kannel WB, Dannenberg AL, Abbott RD. Unrecog-nized myocardial infarction and hypertension. The Framingham Study. Am Heart J. 1985;109(3 Pt 1):581-5.

  5. Pepine CJ. Systemic hypertension and coronary artery diseases. Am J Cardiol. 1998;82(3A):21H-24H.

  6. Pepine CJ, Handberg EM. The Vascular Biology of Hypertension and Atherosclerosis and Intervention with Calcium Antagonist and Angiotensin- Conver-ting Enzyme Inhibitors. Clin Cardiol. 2001;24(11 Suppl):V1-5.

  7. Moreno-Martínez FL, López Bernal O, Cepero Franco S. Anticonceptivos orales y ectasia coro-naria. Clin Invest Arterioscl [Internet]. 2006 [citado 2 Feb 2011];18(5):[aprox. 6 p.]. Disponible en: http://www.elsevier.es/en/node/2049367

  8. Pepine CJ, Abraham J, Marks RG, Morris JJ, Sheidt SS, Handberg E. Caracteristics of contem-porary populations with angina pectoris. TIDES Investigators. Am J Cardiol.1994;74(3):226-31.

  9. Psaty BM, Hechbert SR, Koepsell TD, Siscovich DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihiperten- sive treatments. JAMA. 1995;274(8):620-25.

  10. Erdine S, Handberg E, Kolb B. Characteristics of patients with coronary artery disease and hyperten-sion: a report from INVEST. Clin. Cardiol. 2001; 24(11 Suppl):v6-8.

  11. Pepine C. Introduction: The European INVESTiga-tors Meeting. Clin. Cardiol. 2001;24(11 Suppl):A6.

  12. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-46.

  13. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hyper-tension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990.1996;93(4):697-703.

  14. EUROASPIRE. A European Society of Cardiology Survey of Secondary Prevention of Coronary Heart Disease: Principal results: European Action on Se-condary Prevention through Intervention to Reduce Events. Eur Heart J. 1997;18(10):1569-82.

  15. Celermajer DS, Sorensen KE, Gooch VM, Sullivan ID, Lloyd JK. Deanfield J E, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828):1111-5.

  16. Psaty BM, Smith NL, Siscovich DS. Health outcome associated with antihypertensive thera-pies used as first- line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-45.

  17. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Done-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92(5): 1326-31.

  18. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlin RJ. Los bloqueadores de los canales de calcio en personas hipertensas mayo-res de 67 años. Do Calcium Channel Blockers Increase the Risk of Cancer? Am J Hypertens. 1996;9(7):695-9.

  19. Breslow NE, Day NE. Métodos estadísticos en la investigación de cáncer. Vol. 1. En: El análisis de estudios con control de casos. Lyon: International Agency for Research on Cancer; 1980.

  20. Effects of calcium antagonist on the risk of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hypertens. 1997;15(2): 105-15.

  21. Opie LH, Frishman WH, Thandoni V. Calcium channels antagonists. In: Opie LH, editor. Drugs for the heart. Philadelphia: WB Saunders; 1995. p. 50.

  22. Moreno-Martínez FL, Cepero S, López O, Ramírez M, Monteagudo L. Aspectos clásicos y actualizados acerca de los bloqueadores de los canales de calcio. Revista PortalesMédicos.com. 2005;280(1):[aprox. 5 p.]. Disponible en: http://www.portalesmedicos.com/publicaciones/articles/280/1/Aspectos-clasicos-y-actualizados-acerca-de-los-bloqueadores-de-los-canales-de-calcio.html

  23. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66(10):779-85.

  24. Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O, et al. Car-diac events rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Dannish Verapamil Infarction Trial (DAVIT) Study Group.Am J Cardiol. 1997;79(6):738-41.

  25. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbility and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in The International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Lancet. 2000;356 (9227):366-72.

  26. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen S, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and B- blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDAL) study. Lancet. 2000;356 (9227):351-440.

  27. Deanfield JE, Detry JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery diseases: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol. 1994;24(6):1460-7.

  28. 28.- Savonitto S, Ardissiono D, Egstrup K, Ras-mussen K, Bae EA, Omland T, et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery diseases: Double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol. 1996;27(2):311-6.

  29. The total ischaemic burden European trial (TIBET): design, methodology and management. The TIBET Study Group. Cardiovasc Drugs Ther. 1992;6(4): 379-86.

  30. Von Armin T. Medical treatment to reduce total ischemic burden : total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing biso-prolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25(1):231-8.

  31. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al. Effects of metopro-lol versus verapamil in patients with stable angina pectoris (APSIS). European Heart J. 1996;17(1): 76-81.

  32. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Rationale, design, methods and baseline demography of participants of The Anglo Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19(6): 1139-47.

  33. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis on the occurrence of clinical events. PREVENT Investiga-tors. Circulation. 2000;102(13):1503-10.

  34. Groning E, García Barreto D. Antagonistas del calcio. Rev Cubana Cardiol Circ Cardiovasc. 1989; 4:103-9.

  35. García Barreto D. Los antagonistas del calcio en el tratamiento de la isquemia miocárdica III. Rev Cubana Cardiol Circ Cardiovasc. 1990;4:94-106.

  36. García Barreto D, Toruncha Chukram A. Los inhibidores de la enzima conversora de angioten-sina. Rev Cubana Cardiol Circ Cardiovasc. 1997; 11(1):29-46.

  37. Torp-Pedersen C, Kober L. Effects of ACE-inhibitor on life expentacy of patients with reduced left-ventricular function after myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evalua-tion. Lancet. 1999;354(9172): 9-12.

  38. Hernández Castro A, González A, Cardonne A, Pe-réz Medina T, García Barreto D. Effects of atenolol in angina pectoris of effort. Cor Vasa. 1978;20(2): 99-103.

  39. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens. 1987;5(5); 561-72.

  40. Amery A, Berkenhogen WH, Bulpett CJ, Dollery CT. The European Working Party on High blood pressure in the Elderly. Am J Med. 1991;90(3A)-1S-64S.

  41. Multiple Risk Factor Intervention Trial. JAMA.1982; 248(12):1465-77.

  42. Erdine S, Handberg E, Kolb B. Characteristics of patients with coronary artery disease and hyperten-sion: a report from INVEST. Clin. Cardiol. 2001;24 (11 Suppl):V6-8.

  43. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birbenhager WH, et al. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hyperten-sion. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080): 757-64.

  44. Gruen LM, Pepine CJ. Raising awareness of angina in women. Heart.2007 March;93(3):279-80.

  45. Wallis E, Ramsay L, Jackson P. Cardiovascular and coronary risk estimation in hypertension management. Heart. 2002;88(3):306-12.

  46. Kannel WB, Cupples LA, D’Agostino RB, Stokes J. Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study. Hypertension. 1998;11(3 Pt 2):1145-50.

  47. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Preven-tion, phase II. The Trials of Hypertension Preven-tion Collaborative Research Group. Arch Intern Med. 1997;157(6):657-67.

  48. Stamler R, Stamler J, Gash F, et al. Primary prevention of hypertension by nutritional hygienic means. Final report of a randomized, controlled trial. JAMA. 1989;262 (22):1801-7.

  49. Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in con-trast to betablocker-low-dose chlortalidone treat-ment in hypertensive type 2 diabetes. J Hypertens. 1996;14(5):669-77.

  50. Goodman and Gilmans. The Pharmacological Basis of therapeutics. Philadelphia: McGraw-Hill; 1998.

  51. Hulley S, Ashman P, Kuller L, Lasser N, Sherwin R. HDL-cholesterol levels in the Multiple Risk Factor Intervention Trial (MRFIT). Lipids. 1979; 14(1):119-23.

  52. Moreno-Martínez FL, Escobar Blanco A, Díaz López F, Alegret Rodríguez M, López-Bernal OJ, Aladro Miranda I, et al. Factores de riesgo coro-nario y riesgo cardiovascular en personas adultas de un área de salud de Rancho Veloz (Cuba). Clin Invest Arterioscl. 2008;20(4):151-61.

  53. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349-60.

  54. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial com-paring warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002; 105(5):557-63.

  55. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardio-vascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105(25):2962-7.




2020     |     www.medigraphic.com